Financial Report: Pfizer 3Q11

Pfizer 3Q11

3Q Revenues: $17.2 billion  (+7%)

3Q Earnings: $3.7 billion (earnings were $866 million 3Q10)

YTD Revenues: $50.7 billion (+2%)

YTD Earnings: $8.6 billion (+60%)

Comments: Lipitor sales were $2.6 billion (+3%). Prevnar/Prevenar 13 revenues were up 37% to $1.0 billion. Celebrex sales were $643 million (+11%). Lyrica sales were $961 million (+27%). Pristiq sales were up 24% to $146 million. Legacy King products accounted for $119 million in the quarter. Biopharmaceutical products accounted for $14.7 billion (+6%). U.S. revenues were $6.9 billion, down 3%. International revenues were $10.3 billion, up 15%. Foreign exchange accounted for $951 million, or 6% of growth in the quarter.  Results were favorably impacted by a $1.3 billion gain on the sale of Capsugel in 3Q11, as well as the non-recurrence of impairment charges of $1.5 billion related to certain assets acquired with the Wyeth acquisition and a $701 million charge for asbestos litigation related to subsidiary, Quigley Company, Inc.